- RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc ICPT should be well-capitalized into make-or-break upcoming readouts for obeticholic acid (OCA) in NASH, with REGENERATE re-analyses on deck, REVERSE reading in the next quarter.
- The analysts say it remains challenging to get visibility on how the efficacy/safety analyses will look, how the FDA will interpret the benefit/risk profile from this data, and how effectively ICPT would be able to launch a first NASH agent, if approved.
- RBC increased the price target on ICPT to $18 from $16, with a Sector Perform rating.
- Related: Why Intercept Shares Are Rising Today.
- Raymond James maintains Outperform on ICPT following 1Q22 earnings and views that Ocaliva has a decent chance of approval in F2/F3 NASH (60% in the model).
- The Advanz Pharma deal that licenses OCA in PBC in ex-U.S. markets substantially impacts Raymond James DCF (since we modeled Ex-US risk-adjusted NASH revenues and the upfront doesn’t value NASH opportunity).
- ICPT is targeting June ‘22 for a pre-submission meeting with FDA to discuss an expanded NASH dataset.
- The analysts note three important catalysts for 2022, including REGENERATE re-analysis/pre-submission meeting with the FDA, NDA resubmission, and 3Q22 REVERSE readout in F4 patients, with potential to shift sentiment after ~2 NASH catalyst-free years.
- The analysts lowered the price target from $44 to $23.
- Price Action: ICPT shares are down 3.55% at $18.59 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
